KR20230006473A - 펩티드 태그 및 결합 파트너 - Google Patents

펩티드 태그 및 결합 파트너 Download PDF

Info

Publication number
KR20230006473A
KR20230006473A KR1020227036447A KR20227036447A KR20230006473A KR 20230006473 A KR20230006473 A KR 20230006473A KR 1020227036447 A KR1020227036447 A KR 1020227036447A KR 20227036447 A KR20227036447 A KR 20227036447A KR 20230006473 A KR20230006473 A KR 20230006473A
Authority
KR
South Korea
Prior art keywords
seq
binding partner
peptide tag
peptide
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227036447A
Other languages
English (en)
Korean (ko)
Inventor
시리엘 엘리에트 푸게루
아담 프레데릭 샌더 버텔센
수잔 트레인
Original Assignee
어댑트백 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어댑트백 에이피에스 filed Critical 어댑트백 에이피에스
Publication of KR20230006473A publication Critical patent/KR20230006473A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020227036447A 2020-05-07 2021-05-07 펩티드 태그 및 결합 파트너 Pending KR20230006473A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20173377.1 2020-05-07
EP20173377 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Publications (1)

Publication Number Publication Date
KR20230006473A true KR20230006473A (ko) 2023-01-10

Family

ID=70613720

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036447A Pending KR20230006473A (ko) 2020-05-07 2021-05-07 펩티드 태그 및 결합 파트너

Country Status (11)

Country Link
US (1) US20230321260A1 (https=)
EP (1) EP4146675A1 (https=)
JP (2) JP7843245B2 (https=)
KR (1) KR20230006473A (https=)
CN (1) CN115698045A (https=)
AU (1) AU2021268757A1 (https=)
BR (1) BR112022019632A2 (https=)
CA (1) CA3177709A1 (https=)
IL (1) IL297111A (https=)
MX (1) MX2022013938A (https=)
WO (1) WO2021224451A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US20240240203A1 (en) 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
EP4593874A2 (en) 2022-09-30 2025-08-06 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
GB202317925D0 (en) 2023-11-23 2024-01-10 Spybiotech Ltd Vaccines
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
PL3215614T3 (pl) * 2014-11-03 2019-12-31 Merck Patent Gmbh Rozpuszczalne białka fuzyjne inteiny i sposoby oczyszczania biocząsteczek
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
US11807671B2 (en) * 2016-11-16 2023-11-07 Auckland Uniservices Limited Methods for protein ligation and uses thereof
CN111073925B (zh) * 2018-10-19 2022-04-26 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Also Published As

Publication number Publication date
CA3177709A1 (en) 2021-11-11
BR112022019632A2 (pt) 2023-10-03
EP4146675A1 (en) 2023-03-15
AU2021268757A1 (en) 2022-12-08
MX2022013938A (es) 2022-11-30
WO2021224451A9 (en) 2022-05-27
JP7843245B2 (ja) 2026-04-09
JP2023525752A (ja) 2023-06-19
JP2026048917A (ja) 2026-03-17
US20230321260A1 (en) 2023-10-12
CN115698045A (zh) 2023-02-03
WO2021224451A1 (en) 2021-11-11
IL297111A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
KR20230006473A (ko) 펩티드 태그 및 결합 파트너
AU2020200303B9 (en) Novel multivalent nanoparticle-based vaccines
CN113861278B (zh) 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
HUE029919T2 (en) Genetically modified antibody stress protein fusions
KR20230122019A (ko) 핵산 백신
CN113121704B (zh) 基于纳米颗粒的冠状病毒疫苗
Ramirez et al. Engineering protein nanoparticles functionalized with an immunodominant Coxiella burnetii antigen to generate a Q fever vaccine
US20070092933A1 (en) Production of multimeric fusion proteins using a c4bp scaffold
EP4159864A1 (en) Recombinant expression vector for producing encapsulin-based vaccine, and preparation method therefor
WO2018175560A1 (en) Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
CN114478717A (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
CN116669758A (zh) 核酸疫苗
CN115466330A (zh) 一种基于病毒样颗粒呈递冠状病毒受体结合区的冠状病毒亚单位疫苗
HK40067420B (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40067420A (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
WO2024091589A1 (en) Malaria immunogen and methods for using same
WO2025038373A1 (en) Compositions and methods targeting osteoactivin
HK40067421A (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40067421B (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
CN118725052A (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白
HK40073046A (en) A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof
WO2019198693A1 (ja) 標的分子と結合するポリペプチド
CN121494995A (zh) 一种稳定且具有正确亚复合物形成模式的猴痘病毒a30/h2融合蛋白及其应用
HK40054535A (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof
HK40054535B (en) Recombinant trimeric rbd protein vaccine of novel coronavirus capable of generating broad-spectrum cross-neutralization activity, and preparation method and application thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902